Ocular Therapeutix(OCUL) - 2024 Q3 - Quarterly Results

Exhibit 99.1 Ocular Therapeutix™ Reports Third Quarter 2024 Results and Business Highlights SOL-1 expected to be fully randomized by YE 2024 with topline data expected in Q4 2025 Active clinical trial sites now enrolling patients directly into SOL-R Cash balance of $427.2M as of September 30, 2024, expected to fund operations into 2028 Ocular to host a Q3 2024 conference call and webcast today, November 14th, at 8:00 AM ET BEDFORD, MA, November 14, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: ...